Bruker Co. (NASDAQ:BRKR) – Equities research analysts at William Blair reduced their Q1 2018 earnings per share (EPS) estimates for shares of Bruker in a report issued on Monday. William Blair analyst A. Murphy now anticipates that the medical research company will post earnings of $0.23 per share for the quarter, down from their previous estimate of $0.24. William Blair also issued estimates for Bruker’s Q4 2018 earnings at $0.56 EPS, FY2018 earnings at $1.37 EPS, Q1 2019 earnings at $0.26 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.34 EPS, Q4 2019 earnings at $0.60 EPS, FY2019 earnings at $1.48 EPS and FY2020 earnings at $1.59 EPS.

Several other equities analysts have also issued reports on BRKR. JPMorgan Chase & Co. raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Friday, November 3rd. Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price target on the stock in a research note on Friday, November 3rd. Cowen reissued a “hold” rating and issued a $29.00 target price on shares of Bruker in a research note on Friday, November 3rd. Citigroup increased their target price on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Finally, Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $32.29.

Bruker (NASDAQ BRKR) opened at $31.19 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. Bruker has a one year low of $21.83 and a one year high of $36.53. The stock has a market capitalization of $4,889.33, a price-to-earnings ratio of 25.76, a PEG ratio of 2.10 and a beta of 1.05.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.02. Bruker had a return on equity of 26.58% and a net margin of 4.45%. The business had revenue of $530.50 million for the quarter, compared to analyst estimates of $506.74 million. During the same quarter in the prior year, the firm posted $0.46 earnings per share. The firm’s revenue for the quarter was up 12.8% compared to the same quarter last year.

Several institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its holdings in shares of Bruker by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares in the last quarter. Advisory Services Network LLC increased its holdings in shares of Bruker by 6.3% in the second quarter. Advisory Services Network LLC now owns 6,847 shares of the medical research company’s stock worth $197,000 after acquiring an additional 406 shares in the last quarter. Invictus RG increased its holdings in shares of Bruker by 18.6% in the fourth quarter. Invictus RG now owns 10,398 shares of the medical research company’s stock worth $357,000 after acquiring an additional 1,634 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Bruker by 43.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,586 shares of the medical research company’s stock worth $226,000 after acquiring an additional 1,987 shares in the last quarter. Finally, ETRADE Capital Management LLC increased its holdings in shares of Bruker by 10.1% in the third quarter. ETRADE Capital Management LLC now owns 29,484 shares of the medical research company’s stock worth $877,000 after acquiring an additional 2,701 shares in the last quarter. Institutional investors own 64.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Q1 2018 EPS Estimates for Bruker Co. Cut by William Blair (BRKR)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/02/14/q1-2018-eps-estimates-for-bruker-co-cut-by-william-blair-brkr.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.